Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin alfa in adults with known or suspected F2/F3 MASH
NL-OMON61242Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by GSK. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Treatment-emergent adverse events leading to discontinuation and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON61242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61242.